Parenteral Drugs (India) Limited Share Price NSE India S.E.

Equities

PDPL

INE904D01019

Pharmaceuticals

Market Closed - NSE India S.E. 12:40:39 21/08/2023 BST 5-day change 1st Jan Change
2.9 INR +1.75% Intraday chart for Parenteral Drugs (India) Limited -.--% -.--%

Financials

Sales 2020 319M 3.82M 305M Sales 2021 122M 1.46M 116M Capitalization 94.52M 1.13M 90.39M
Net income 2020 -1.14B -13.68M -1.09B Net income 2021 -1.22B -14.59M -1.16B EV / Sales 2020 20.2 x
Net Debt 2020 6.35B 76.18M 6.08B Net Debt 2021 6.36B 76.19M 6.08B EV / Sales 2021 53 x
P/E ratio 2020
-0.07 x
P/E ratio 2021
-0.08 x
Employees 909
Yield 2020 *
-
Yield 2021
-
Free-Float 23.67%
More Fundamentals * Assessed data
Dynamic Chart
1 year
2.70
Extreme 2.7
3.40
3 years
2.50
Extreme 2.5
4.80
5 years
2.20
Extreme 2.2
7.45
10 years
2.20
Extreme 2.2
82.65
More quotes
Managers TitleAgeSince
Director of Finance/CFO 74 31/12/88
Chairman 70 12/12/83
Members of the board TitleAgeSince
Chairman 70 12/12/83
Director/Board Member 78 30/01/06
Director of Finance/CFO 74 31/12/88
More insiders
Parenteral Drugs (India) Limited is engaged in the manufacturing of pharmaceutical products. It also manufactures intravenous (IV) infusion, inhalation, and veterinary infusion. It offers products in various categories, including IV fluids, oncology, anesthesia and exports. Its IV Fluids include Carbohydrated and Electrolytes, such as Dextrose IP 5%, 10%, 20%, Dextrose IP 25% , and Ringer Lactate IP; Diuretics, such as Mannitol 10%, 20% and Manidex (Mannitol 10% with Glycerine 10%); Dialysis and Irrigation Solution, such as Peritoneal Dialysis Solution with 1.7% Dextrose and 1.5% Glycine; Anti-infective and Anti-fungal, such as Ciprofloxacin 200mg and Metronidazole 500mg and others , such as Tamolgan (Paracetamol 1000mg) and PD-Invert (10% Invert Sugar). Its Oncology product mix includes 5 FU-PAR and BAZIPAR. Its Anesthesia product mix includes Sevoplan (Sevoflurane 100/250ml) and Isoplan (Isoflurane 100/250ml).
More about the company